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1. INTRODUCTION
1.1. Osteoarthritis
Osteoarthritis (OA) is a chronic degenerative disease of the joints in the human body
(1,2).  It  is  the  most  common  form  of  arthritis  nowadays  affecting  250  million  people
worldwide  (3,4).  The  most  frequent  risk  factors  are  obesity,  trauma,  age  and  genetic
predisposition. OA can be classified as primary (idiopathic, multifactorial and unkown cause)
and secondary (following fractures, joint infections, angular deformities, joint dysplasias etc.)
(3,5,6). Furthermore, OA is characterized mainly by deterioration of articular cartilage most
commonly in the hip, knee, proximal interphalangeal joint (PIP) and distal interphalangeal
joint (DIP) (1). Patients classically suffer from crepitus, decreased range of motion, stiffness,
swelling  in  the  morning that  deteriorates  during  the  day and most  importantly  pain  with
activity that improves with rest (2,7). It is diagnosed by anamnesis, clinical examination and
imaging studies such as x-ray or magnetic resonance imaging (MRI) indicating joint space
narrowing  with  osteophytes  and  subchondral  sclerosis  (7).  The  American  College  of
Rheumatology have created criteria that are frequently used for the clinical diagnosis of hip
OA (Table 1).  In addition, synovial fluid may be extracted and analyzed. Fluid in OA will be
straw-colored and will contain less than 2000 cells/µl (7).  Even though OA is not considered
to be an inflammatory disease without elevated markers, it should be noted that there is local
inflammation like synovitis. However, it is not known whether the inflammatory reaction is
induced by it or whether this is secondary to changes of OA (3,7). Furthermore, cartilage itself
is  incapable  of  inducing  pain  or  inflammation  since  there  is  lack  of  vasculature  and
innervation  (3,8,9).  This  means  that  pain  must  derive  from other  joint  components,  like
synovium, joint capsule, ligaments, subchondral bone and muscles (3,8,9).
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Table 1. American College of Rheumatology criteria for the diagnosis of hip osteoarthritis 
(10)
Clinical criteria A Clinical criteria B Clinical plus radiographic 
criteria
Hip pain; and
Hip internal rotation <15°; 
and
ESRa ≤45mm/h or hip flexion
≤115° if ESR unavailable
Hip pain; and
Pain with internal hip 
rotation; and
Morning stiffness of hip 
≤60min; and
Over 50years of age
Hip pain; and any 2 of the 
following:
ESR <20mm/h
Radiographic femoral and/or 
acetabular osteophytes
Radiographic joint space 
narrowing
a Erythrocyte Sedimentation Rate
Unfortunately,  conservative  treatment  is  limited  to  physical  therapy,  weight  loss,
chronic intake of NSAIDs and intraarticular injections of cortisone, viscosupplements, platelet
rich plasma and bone marrow aspirate concentrate (7,11,12). Consequently, the only definite
treatment is joint replacement in advanced cases (7,11). Since our population is growing older
and becoming more obese it is of utmost importance to further investigate this disease (7).
1.2. Pathogenesis of osteoarthritis
The pathogenesis of OA is multifactorial and mainly based on pathologic changes in
the  articular  cartilage,  subchondral  bone  and  synovium  (3,13,14).  One  major  cause  is
biomechanical stress from trauma, abnormal joint morphology and increased weight bearing
on articular cartilage (3,6,13). This results in damage to the homeostatic balance of synthesis
and degradation of joint tissue consequently leading to end stage OA (13). Repetitive shear
stress in  the joint  from trauma or  obesity has been affiliated with molecular  and cellular
changes, such as increased expression of pro-inflammatory mediators and increased apoptotic
activity  (13,15).  Following  the  primary  cartilage  damage,  segments  of  chondrocytes  and
extracellular matrix (ECM) are liberated in the synovial fluid (14). Upon extraction, it was
observed  that  it  included  many  inflammatory  factors  such  as  C-reactive  protein  (CRP),
prostaglandins (PGE), leukotrienes (LKB4), complement constituents, cytokines (TNF, IL1β,
IL6,  IL15,  IL17,  IL18,  IL21),  induced  nitric  oxide  synthase  (iNOS)  and  growth  factors
(TGFβ, FGFs, VEGF, NGF) produced by components of the joint including chondrocytes,
subchondral osteoblasts and synovial membrane (3,14,15). Locally,  these constituents may
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initiate the matrix metalloproteinases (MMPs) and other hydrolytic enzymes (cyclooxygenase
2 (COX2) and PGE) to damage collagen and proteoglycans resulting in articular cartilage and
ECM  breakdown (3,14).  These  proinflammatory  mediators  are  transcribed  by  the
transcription factor NF κB, activated by synovial membrane inflammation (14). In order to‐
protect  itself,  ECM  breakdown  liberates  damage-associated  molecular  patterns  that  are
identified by the innate immune cells, such as macrophages and mast cells (3). However, this
overwhelming extent of inflammation can cause damage to the underlying tissue (3). In fact,
osteophytes  were  identified  to  be  caused  partially  by  macrophages  researched  in  animal
studies  (3).  Usually,  humans  have  protective  growth  factors,  such  as  fibroblast  18  or
transforming growth factor B (3). However, in for example knee OA they are altered and can
thus become harmful (3). 
The area between subchondral bone and articular cartilage, called the osteochondral
junction,  has  also  been  found  to  be  an  important  component  of  OA (13,16,17).  Both
constituents  work  together  by  adapting  in  an  organized  manner  to  changed  biochemical
loading (13). Whenever there is an increased stress on the joint both components react in
different  ways  (13).  While  subchondral  bone  reacts  with  accellerated  degree  of  turnover
manifesting  as  deterioration  of  subchondral  and  trabecular  bone  structure,  the  articular
cartilage experiences microcracks due to microdestruction allowing increased vascularization
(13,16).  This  causes  a transit  of cytokines  and growth factors  in  both directions  bridging
cartilage and subchondral bone not only mechanically but also biochemically (13,16). The
exact molecules have not been entirely researched but it  is thought that pro-inflammatory
cytokines and osteoclast-stimulating factors liberated by the damaged cartilage move towards
the subchondral bone causing a change in its structure (13). And pro-inflammatory signalling
molecules liberated by osteoblasts from subchondral bone move towards articular cartilage
causing degradation (13).
It has also been researched that synovitis is a common finding in OA (3,18). Normally,
synovial membrane is made up of two layers intima and subintima consisting of cells, like
macrophages,  fibroblast like  synoviocites  (FLS),  smooth  muscle  cells  and endothelium of‐
blood vessels (14,18,19). But during inflammation, the synovial surface cell layer is thickened
and contains inflammatory cells, such as lymphocytes and plasma cells. Moreover, one can‐
find neoangiogenesis and fibrosis during inflammation (14,18,19). 
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  When visualizing synovitis under arthroscopy, MRI, ultrasound (US) and biopsies,
one can see that the inflammation and its symptoms appear before the bony changes occur
(14,19).  Therefore,  since  there  is  increased  joint  instability  and  primary  damage  to  the
articular cartilage in the early stage, synovial inflammation actually has more significance
then (14). Moreover, increased hyperplasticity and inflammation from increased vascularity,
synovial  line  thickness  and expression  of  inflammatory factors  were  more pronounced in
early stage when compared to advanced OA (14). However, it is important to note that even
though more inflammatory factors are present in early stage, synovial membrane may be more
substantial in the advanced stage (14).
1.3. Syndecan-1 and its role in osteoarthritis
Syndecan-1 belongs to the family of Syndecans (20,21). They are transmembrane cell
surface  proteoglycans  that  carry  glycosaminoglycan  (GAG)  chains,  such  as  heparan  and
chondroitin sulphate, which are covalently bound to the core protein (20,22). Syndecans and
MMPs work together on keeping the normal ECM homeostasis in balance (22). In addition,
they react to inflammatory signals by stimulating a disintegrin  and metalloproteinase with
thrombospondin motifs (ADAMTS) proteinases causing division of aggregated proteoglycans
(15,22). This shows that Syndecans may be implicated in modification of cellular activities
such  as  proliferation  and  differentiation  (22).  Moreover,  Syndecans  are  known  to  be
coreceptors for cytokines and more importantly ECM receptors that cause cell adhesion with
the matrix and other cells (20,22). Therefore, Syndecans may have a role in angiogenesis and
migration of leukocytes which are essential constituents of disease development for synovitis
(20).  In fact, Heparan sulfate chains specific for Syndecans also affect osteoblastogenesis and
osteoclastogenesis which are both associated with OA (22). 
So far, four Syndecans have been recognized (20,21). Firstly, Syndecan-1 is expressed
mainly on epithelial cells but can also be found on endothelial cells (20,21). Syndecan-2 is
mostly expressed on fibroblasts,  carcinogenous and endothelial  cells  (20,21).  Syndecan-3,
however,  is  found mostly in  musculoskeletal  and neuronal  cells,  specifically in cerebellar
fibrillar  plaques  in  Alzheimer  (20,21).  Lastly,  Syndecan-4  can  be  found  on  many  cells
including endothelial and epithelial (20).
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Focusing on Syndecan-1, it is expressed in many different developmental processes,
such as tissue organization,  like angiogenesis  and wound healing and limb bud and tooth
development.  Moreover,  it  is  also  found  to  be  associated  with  not  only  controlling
inflammatory responses but also attaching to chemokines and causing chemokinetic gradients
(20,21). 
Increased expression in OA due to proliferation of chondrocytes has been detected
(22). Previous research on mice has shown that in early OA maturing chondrocytes classically
change their phenotype, similar to tissue repair, producing not only more type IIa procollagen
but also transcription factor Sox9 (22). However, this does not suffice as the cartilagenous
damage continues to endstage OA (22). This repair is very similar to that of wounds in which
Syndecan-1 plays a crucial role which is why it was chosen for further investigation (22). 
1.4. HSP-70 and its role in osteoarthritis
HSP-70  belongs  to  the  family  of  heat  shock  proteins  where  the  70  indicates  its
molecular  weight  measured  in  kDa  (23).  Another  name  for  HSP-70  is  stress  protein  or
molecular chaperone (24). This is because chondrocytes, when exposed to environmental or
mechanical stress, start producing it in high numbers after being stimulated by IL-1, IL-2 and
tumor necrosis factor alpha (TNFalpha) (23,24). HSP-70's physiologic role is to protect the
structural integrity and cellular proteins by inhibiting multiple pathways of apoptosis, such as
Nitric Oxide (NO) induced caspase 3, the previously mentioned NF κB, JNK, apoptosome‐
formation and mitochondrial cytochrome C release (23-26). Moreover, it protects the cells
from oxidative stress which otherwise would result in apoptosis and necrosis (23). 
Furthermore, it  has been researched in rats, when exposed to different severities of
exercise, that little and intermediate workout increased HSP-70 expression actually preventing
OA by promoting cell metabolism to provide enough sulfated glycosaminoglycan (sGAG) to
the ECM in the joint as shown in figure 1 (26). However, severe exercise resulted in OA
despite increased HSP-70 potentially exceeding its capacity of protection (26). This may be
due to increased expression of HSP-90 which was found to restrict the properties of HSP-70
and activate the NF κB which is a major factor in the pathogenesis of OA (26).  ‐  
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Figure 1. Representation of hypothetical roles of HSP-70 and HSP-90 in osteoarthritis (OA).
Healthy cartilage (A). Stressed cartilage during running (B). Persisting biomechanical stress
(C). Osteoarthritis (D) (26).
Clearly, HSP70 has some important role in the pathogenesis and development of OA
which is why it was also chosen for the purpose of this paper.
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 2. OBJECTIVES
The purpose of this study was to investigate the expression of Syndecan-1 and HSP-70
in synovial, chondral and subchondral tissue in the hip of human patients with osteoarthritis
according to their disease severity. Since OA in the knee has been researched frequently the
interest  was  whether  the  same  process  with  the  same  markers  also  occurs  in  the  hip.
Depending on the results, the expression could be the aim of a new pharmacologic agent
targeting Syndecan-1 and HSP-70 to ameliorate the symptoms of osteoarthritis in the hip.
Hypothesis
Syndecan-1 and HSP-70 are overly expressed in synovial, chondral and subchondral
tissue in patients with severe osteoarthritis of the hip.
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3. MATERIALS AND METHODS
3.1. Ethical background
The experimental protocol was approved by the Ethics Committee of the University
Hospital Split. All performed procedures were in compliance with the ethical standards of the
institutional research committee and the 1964 Helsinki declaration.
3.2. Study design
This  cross-sectional  study  was  performed  in  the  Department  of  Orthopedics  and
Traumatology of the University Hospital  Split  (KBC) and in the Department of Anatomy,
Histology and Embryology of the University of Split School of Medicine. The tissue was
collected in the period of 2017 to 2018.
3.3. Study population
Eight patients were included in this study. Six patients were diagnosed with severe
osteoarthritis  of  the  hip  by  an  orthopedic  surgeon  on  the  basis  of  anamnesis,  clinical
examination and standard hip x-ray. The other two patients underwent total hip replacement
for a femoral neck fracture and were used as control. Patients were included and excluded
according  to  the  American  College  of  Rheumatology  criteria  for  the  diagnosis  of  hip
osteoarthritis. In addition, they were scored according to the Harris Hip Score, Oxford Hip
Score and the radiologic Kellgran Lawrence grading scale. In order to be put in the group of
severe OA they had to reach a Kellgran Lawrence grade of at least 3, an Oxford Hip Score of
maximally  27  out  of  48  (48  meaning  least  dysfunction)  and/or  a  Harris  Hip  Score  of
maximally 70 out of 100 (100 meaning least dysfunction) (27). The patients used as control
all had Kellgran Lawrence grades of 0 or 1. The Oxford Hip Score and the Harris Hip Score
were not able to be assessed in these patients with a femoral neck fracture since these two
scores assess the range of motion.
3.4. Tissue collection
Total  hip  arthroplasty  was  performed  on  included  patients  (Implant:  Pinnacle
Acetabular Cup System and Corail Hip System by Depuy, Johnson and Johnson, USA).
Then, tissue from the weight bearing area of the pathologic femur adjacent to the most
damaged but  still  cartilage  containing  zone was  removed in  a  triangular  manner  with  an
oscillating saw (Trauma Reckon Sytem by Synthes, Switzerland) and was put in a sterile
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plastic cup used for pathohistology to be sent to the laboratory. Originally,  the tissue was
collected in a transverse manner from the weightbearing area as seen in figure 2. However,
this  resulted  in  too  big  of  tissue  sample  which  was  not  optimal  for  the  process  of
decalcification with osteosoft and further analysis with immunohistochemistry.
Figure  2. Tissue  extraction.  Original,  not  optimal  transverse  collection  (A)  and  ideal
triangular collection used for this research (B).
3.5. Immunohistochemistry
The  tissue  samples  were  collected  and  fixed  in  4%  Paraformaldehyde  (PFA)  in
Phosphate buffered saline (PBS) overnight and transferred to osteosoft solution for 6 months.
In the pilot study we used four samples and titrated an appropriate time for incubation of
osteosoft (from one, two, three and four months). However, the results were not optimal for
further analysis because the decalcification process was not complete. Therefore, we collected
new samples and incubated them for 6 months. 
The tissue samples were then embedded in paraffin blocks and cut transversely (7 µm thin
sections) and mounted on slides. These were then deparaffinated in Xylol for three times five
minutes. 
12
Following this, they were rehydrated two times for ten minutes in 100% ethanol, five
minutes in 95% ethanol, five minutes in 70% ethanol and five minutes in distilled water. Next,
the slides were heated in citrate buffer (pH 6.0) at 700 Watt in a microwave for 12 minutes.
After they had cooled off at room temperature for 20 minutes the slides were rinsed with PBS
for four times five minutes. Afterwards, they were dried and the tissue was encircled by a PAP
pen. Block protein was then put on the tissue sections for 30 minutes. After the block protein
was removed and the slides  had dried  the  primary antibodies  were applied on all  of  the
sections except for one which was used as negative control. The two antibodies from Abcam
(Cambridge, England) used were raised in mouse (ab34164-100) diluted at 1:100 targeting
Syndecan-1 and in rabbit (ab31010) diluted at 1:500 targeting HSP-70. They were kept over
night covered by parafilm in a humidified dark chamber at room temperature. 
The next day the slides were rinsed with PBS two times for five minutes. Afterwards,
the secondary antibodies were applied for one hour. The secondary antibodies from Abcam
(Cambridge, England) for Syndecan-1 were raised in goat (ab6786) diluted at 1:400 appearing
red  on immunofluorescence  and the  ones  for  HSP-70 were  raised  in  donkey (ab150073)
diluted at 1:400 appearing green on immunofluorescence. The slides were then again rinsed
with  PBS  twice  each  for  five  minutes  before  4',6-diamidino-2-phenylindole  (DAPI)  for
nuclear staining was applied for two minutes. Following this, they were again rinsed with
PBS  twice  for  five  minutes  and  dried.  Lastly,  they  were  mounted  in  Immu-mont  and
coverslipped in order to observe and capture images of the sections using an Olympus (Tokyo,
Japan) BX51 microscope equipped with an Olympus (Tokyo, Japan) DP71digital camera.
All images were observed and saved with CellA Imaging Software for Life Sciences
Microscopy from Olympus (Tokyo, Japan). The sections were analyzed focusing mainly on
synovial, chondral and subchondral tissue. Ten non overlapping fields were taken using 40×
objective magnification, each field representing three images. One for Syndecan-1 expression,
one for HSP-70 expression and one for nuclear expression with DAPI. These images were
then further observed and merged using Adobe Photoshop (Adobe Systems, MI, USA). The
cells staining positively for Syndecan-1 and HSP-70, respectively, and all the nuclei stained
with DAPI were counted using ImageJ software (National Institutes of Health, Bethesda, MD,
USA).
The number of positive and negative nuclei from all usable merged images for each
patient was calculated and compared between groups (control and severe OA).
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3.6. Statistical analysis
Data analysis was conducted with GraphPad Prism (GraphPad Software, La Jolla, CA,
USA) and Mann-Whitney t-test was used for statistical analysis to examine the difference
between control and severe OA in the cartilage, subchondral and synovial tissue. Data was
expressed as mean ± standard deviation and statistical significance was p < 0.05.
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4. RESULTS
Immunohistochemical  staining  with  Syndecan-1  and  HSP-70  antibodies  revealed
positive expression of both markers as seen in Figure 3. 
Figure 3. HSP-70 positive cells were seen as green staining (arrows) and Syndecan-1 as red
staining within different areas of the chondral and synovial tissue. Co-localization of HSP-70
&  Syndecan-1  merged  with  DAPI  nuclear  stain  are  displayed  in  the  far  right  column
(arrowheads). Control patients (a) and patients with severe osteoarthritis (b). Scale bar for a is
17µm and for b 10µm. Legend: s- synovium; sc- subchondral tissue; c- cartilage; OA- severe
osteoarthritis 
The  following  charts  (Figures  4-8)  demonstrate  the  amount  of  cell  positivity  in
cartilage and subchondral tissue in the control patients with mild OA and patients with severe
OA according to Harris Hip Score, Oxford Hip Score and Kellgran Lawreence grading. One
can  see  that  the cartilage  and  subchondral  tissue  in  patients  with  severe  OA contained
abundant positive cells with a mean positive cell count of 120±16 and 142±23 for Syndecan-1
and 120±24 and 136±28 for HSP-70, respectively. On the contrary, the control patients only
had minimal positivity with a mean positive cell count of 30±4 and 34±16 for Syndecan-1 and
30±5 and 33±22 for HSP-70, respectively. Synovial tissue could not be identified enough for
presentation. However, it followed the trend of chondral and subchondral tissue. 
It  was  established that  there was a  statistical  significance of both Syndecan-1 and
HSP-70 with p < 0.05 in cartilage and p < 0.001 in subchondral tissue between control and
severe OA. 
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Figure 4. Mean positive  cell  count  of  Syndecan-1 in  cartilage  and subchondral  tissue in
control and severe OA. Data are presented as mean±SD.
Figure 5. Mean positive cell count of HSP-70 in cartilage and subchondral tissue in control
and severe OA. Data are presented as mean±SD.
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Figure 6. Mean positive cell count of HSP-70 and Syndecan-1 coexpressed in cartilage and
subchondral tissue in control and severe OA. Data are presented as mean±SD.
Figure 7. Mean positive cell count of Syndecan-1 and HSP-70 in cartilage in control and
severe OA. Data are presented as mean±SD.
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Figure  8. Mean  positive  cell  count  of  Syndecan-1  and HSP-70 in  subchondral  tissue  in
control and severe OA. Data are presented mean±SD.
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5. DISCUSSION
The results of immunohistochemical staining in this study show that there in fact is an
increased expression of Syndecan-1 and HSP-70 in chondral, subchondral and synovial tissue
of patients with severe OA in comparison with the control patients. Both markers were found
abundantly in cartilage, subchondral and synovial tissue.
When interpreting the results  one can say that there is  an increase in cells  due to
damage of cartilage and a resulting proliferation of chondrocytes trying to repair the damage.
Moreover,  the  inflammation  of  the  synovium  causes  an  increase  in  synovial  lining  cell
thickness.  Also,  the  accellerated  turnover  of  subchondral  bone  as  a  reaction  to  structual
damage is a cause for increased cell production. The reason for a higher number of cells in
subchondral tissue compared to cartilage is probably the more developed vascularity and the
resulting higher differentiation of cells in the subchondral tissue. Nevertheless, there is also an
increased hyperplasticity and layering in the cartilage in the patients with severe OA, whereas
normally the cartilage is lined with only one layer. 
Most  of  these  chondral,  subchondral  and  synovial  cells  were  found  to  coexpress
Syndecan-1 and HSP-70. This can be explained by the fact that in the chondral, subchondral
and synovial tissue Syndecan-1 becomes expressed by the proliferating cells that try to repair
the  damage.  In  this  way,  Syndecan-1  can  trigger  angiogenesis  and attach  to  chemokines
provoking a chemokinetic gradient similar to wound healing. In addition, the proliferating
cells also produce HSP-70 to protect their structure and proteins since it inhibits apoptosis
inducing pathways.
There is a lack of similar studies on this topic since most research papers focused on
the  knee.  Nevertheless,  results  were  all  alike.  When  tested  on  knees  in  mice,  Salminen-
Mankonen et  al.  also proved an upregulation of  Syndecan-1 in  OA of the knee (22).  He
attributed it to the body's attempt to repair the damage that had taken place in the joint (22).
Furthermore,  increased  expression  of  Syndecan-1 in  OA and decreased  expression  in  the
control group is in concordance with Patterson et al. who demonstrated a similar increase in
heparan sulfate proteoglycans (HSPGs) in inflammatory diseases of the knee in his study in
2007 (20). 
Focusing on HSP-70, results of other studies also correlate with our findings. Grossin
et al. transduced chondrocytes with HSP-70 vectors and found out that these cells were not
only  more  resistant  to  cell  death  but  also  that  overexpression  of  HSP-70  decreased  the
severity of OA in rats (28). Furthermore, in 2018 Ngamurkos et al. came to the conclusion
21
that HSP-70 levels in human knees were increased according to their disease severity and that
it could be used as a biomarker for the prediction of OA severity (23). Nevertheless, HSP-70
overexpression alone might  not be sufficient  in  protection of cartilage (26).  According to
Siebelt  et  al.,  HSP-90 might  play a  bigger  role  (26).  They suggested that HSP-70 is  less
responsive to a higher load because HSP-90 restricts its action in increased biomechanical
stress  (26).  When  inhibiting  HSP-90  in  rats  they  realized  that  it  not  only  improved
subchondral bone thickness but also reduced macrophage activation (26). Further research is
needed in order to find out the exact correlation between HSP-70 and HSP-90 in humans
since this could be a possible therapeutic intervention to impede OA. 
One of the limitations of our study was that we did not have another group without any
OA to see a baseline and whether there is a constant rise in Syndecan-1 and HSP-70. Since
most people have at least mild OA in their sixties and total hip replacement is usually not
done before it is difficult to find a group without any OA. However, this was beyond the
scope of this research. In addition, the sample size could be increased in the next studies as we
only included 6 patients with severe OA and only 2 as controls. Moreover, since there wasn't
enough synovial tissue identified it was not possible to present tangible results. Nevertheless,
the trend was similar to that of chondral and subchondral tissue. For future research it would
be important to extract solely synovium. 
In conclusion, the results of our study strongly suggest that HSP-70 and Syndecan-1
play an important role in the onset and regulation of OA in the hip and that they do not differ
from results in previous research on the knee. They are part of the process that tries to heal or
protect  the chondral,  subchondral  and synovial  tissue in  the hip by causing angiogenesis,
increasing  inflammatory  cells  and  preventing  apoptosis.  This  means  that  pharmaceutical
agents might help by increasing the expression of HSP-70. However, increasing HSP-70 alone
might not work since HSP-90 will limit its activity in severe OA as mentioned previously. It
would be important to create an agent that can enhance HSP-70 and block HSP-90 at the same
time.  On  the  contrary,  overexpression  of  Syndecan-1  will  increase  inflammation  and
exacerbate  symptoms.  Consequently,  a  pharmaceutical  drug  blocking  Syndecan-1  could
decrease the inflammatory response and its associated symptoms. 
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6. CONCLUSIONS
1. Patients with severe osteoarthritis had increased staining of Syndecan-1 and
HSP-70 in  the  cartilage  of  the  hip  compared  to  patients  who underwent  total  hip
replacement for a femoral neck fracture.
2. Patients with severe osteoarthritis had increased staining of Syndecan-1 and
HSP-70 in the subchondral tissue of the hip compared to patients who underwent total
hip replacement for a femoral neck fracture.
3. Increased  expression  implies  that  Syndecan-1  and  HSP-70  could  play  a
significant role in the complex pathophysiology of osteoarthritis but further research is
needed in order to make these findings applicable for clinical treatments.
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8. SUMMARY
Objectives:  The purpose of this  study is to investigate the expression of Syndecan-1 and
HSP-70  in  synovial,  chondral  and  subchondral  tissue  in  the  hip  of  human  patients  with
osteoarthritis according to their disease severity. 
Materials and methods: Total hip arthroplasty with tissue extraction from the weightbearing
area of the pathologic femoral head was performed on all patients. Patients were divided into
two groups according to their disease severity defined by their Kellgran Lawrence, Harris Hip
and  Oxford  Hip  Score:  control  (femoral  neck  fracture)  and  severe  Osteoarthritis  (OA).
Chondral,  subchondral  and  synovial  tissues  were  analyzed  with  raised  antibodies  against
Syndecan-1 and HSP-70.
Results:  Immunohistochemical  staining with Syndecan-1 and HSP 70 antibodies revealed
positive expression of both markers. It was established that  the chondral, subchondral and
synovial tissue in patients with severe OA contained abundant positive cells  with a mean
positive cell count of 120±16 and 142±23 for Syndecan-1 and 120±24 and 136±28 for HSP-
70, respectively.  On the contrary, patients without OA had only minimal positivity with a
mean positive cell count of 30±4 and 34±16 for Syndecan-1 and 30±7 and 33±22 for HSP-70,
respectively.  Synovial  tissue could not  be  identified enough for  presentation.  However,  it
followed the trend of chondral and subchondral tissue. It was established that there was a
statistical significance of both Syndecan-1 and HSP-70 with p < 0.05 in cartilage and p <
0.001 in subchondral tissue between control and severe OA. 
Conclusions:  Patients with severe osteoarthritis had increased staining of Syndecan-1 and
HSP-70  in  the  cartilage  and  subchondral  tissue  of  the  hip  compared  to  patients  who
underwent total hip replacement for a femoral neck fracture. Increased expression implies that
Syndecan-1 and HSP-70 could play a  significant  role  in  the complex pathophysiology of
osteoarthritis but further research is needed in order to make these findings applicable for
clinical treatments.
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9. CROATIAN SUMMARY
Naslov: EKSPRESIJA PROTEINA SINDEKAN-1  I  HSP-70  U TKIVU PACIJENATA S
TEŠKIM OSTEOARTRITISOM KUKA
Ciljevi: Svrha ovog istraživanja bila  je  usporediti  razinu ekspresije  proteina  sindekan-1 i
HSP-70 u sinoviji, hrskavici i subhondralnoj kosti pacijenata s teškim osteoartritisom (OA)
kuka i pacijenata bez osteoartritisa.
Materijali  i  metode: Sukladno  težini  pripadajuće  bolesti,  određenoj  prema  Kellgren-
Lawrence,  Harris  Hip  i  Oxford  Hip  klasifikaciji,  ispitanici  su  podijeljeni  u  dvije  grupe:
eksperimentalna  grupa  (teški  OA)  i  kontrolna  grupa  (prijelom  vrata  femura).  Svim
ispitanicima učinjena je totalna artroplastika kuka s ekstrakcijom patološki oštećenog tkiva.
Ekstrahirano tkivo sinovije, hrskavice i subhondralne kosti je imunohistokemijski analizirano
pri čemu su korištena protutijela na sindekan-1 i HSP-70.
Rezultati: Imunohistokemijska analiza s protutijelima na sindekan-1 i HSP-70 pokazala je
pojačanu  ekspresija  obaju  proteina  u  hrskavici  (H)  i  subhondralnoj  kosti  (SHK)  u
eksperimentalnoj grupi u odnosu na kontrolnu. Zbog nedovoljno ekstrahiranog sinovijalnog
tkiva, na sinoviji nije bilo moguće pouzdano usporediti grupe, no dojam je da bi rezultat bio
sukladan onom u H i  SHK. U pacijenata s  teškim OA, u H i  SHK, zabilježeno je obilje
''pozitivnih'' stanica sa srednjom vrijednošću od 120±16 i 142±23 za sindekan-1 te 120±24 i
136±28 za HSP-70. U pacijenata bez osteoartritisa zabilježena je blaga ekspresija ispitivanih
proteina  u  H  i  SHK  sa  srednjom  vrijednošću  ''pozitivnih  stanica''  od  30±4 i  34±16 za
sindekan-1 te  30±7 i  33±22 za HSP-70.  Utvrđena razlika u ekspresiji  navedenih proteina
statistički je značajna s razinom značajnosti p<0,05 za hrskavicu i p<0,001 za subhondralno
tkivo.
Zaključci: Ekspresija  proteina  sindekan-1  i  HSP-70  u  hrskavici  i  subhondralnoj  kosti
pacijenata  s  teškim  osteoartritisom  kuka  je  značajno  veća  u  odnosu  na  pacijente  bez
osteoartritisa. Povećana ekspresija proteina sindekan-1 i HSP-70 sugerira moguću značajnu
ulogu navedenih proteina u složenoj patofiziologiji osteoartritisa. Ipak, daljnja istraživanja su
nužna da bi nalazi ovog istraživanja našli mjesto u kliničkoj promjeni.
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